<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02629146</url>
  </required_header>
  <id_info>
    <org_study_id>GabA01</org_study_id>
    <nct_id>NCT02629146</nct_id>
  </id_info>
  <brief_title>Analgesic Effects of Midazolam in Human Volunteers</brief_title>
  <acronym>GabA01</acronym>
  <official_title>A Single Center, Prospective, Randomized, Double Blind, Placebo-controlled, Three-way Cross-over Study of the Analgesic Effects of Midazolam Versus Placebo With Fentanyl as an Active Control in Human Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wilhelminenspital Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Akron Molecules AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Wilhelminenspital Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates analgesic properties of midazolam compared to placebo and fentanyl. Each&#xD;
      participant will receive all three drugs (midazolam, fentanyl, placebo) on three different&#xD;
      occasions (study visits) and the effect on different pain stimuli will be tested.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in pain ratings (0-100) to a suprathreshold heat pain stimulus</measure>
    <time_frame>3.5 Minutes after end of infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in pain ratings to a suprathreshold electrical pain stimulus</measure>
    <time_frame>3.5 Minutes after end of infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase of pressure pain thresholds (kPa)</measure>
    <time_frame>Up until 23 Minutes after end of infusion</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Analgesic Drugs</condition>
  <condition>Antinociceptive Agents</condition>
  <arm_group>
    <arm_group_label>Midazolam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Midazolam (experimental)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Isotonic saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: Isotonic saline (placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fentanyl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: Fentanyl (active comparator)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <arm_group_label>Midazolam</arm_group_label>
    <other_name>Dormicum</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <arm_group_label>Fentanyl</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotonic saline</intervention_name>
    <arm_group_label>Isotonic saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  male and female volunteers&#xD;
&#xD;
          -  18-40 years old&#xD;
&#xD;
          -  healthy&#xD;
&#xD;
          -  body mass index between 5th and 85th percentile&#xD;
&#xD;
          -  Caucasian&#xD;
&#xD;
          -  non smoker or moderate smoker (&lt;10 cigarettes per day)&#xD;
&#xD;
          -  able to understand, write, and read German&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  acute or chronic pain condition (except for mild day-to-day pain on &lt;5 days/month)&#xD;
&#xD;
          -  previous (up to 5 days preceding the study) or current medications prescription or&#xD;
             over-the-counter, especially analgesics&#xD;
&#xD;
          -  symptoms of a clinically relevant illness in the 2 weeks before the first study day&#xD;
&#xD;
          -  hypertension&#xD;
&#xD;
          -  any known psychiatric condition&#xD;
&#xD;
          -  abuse of alcoholic beverages, drug abuse&#xD;
&#xD;
          -  known positive human immunodeficiency virus status&#xD;
&#xD;
          -  any known medical condition which may interact with study medication, study&#xD;
             objectives, or compliance of subject with study tasks&#xD;
&#xD;
          -  participation in a clinical trial in the 4 weeks preceding the study&#xD;
&#xD;
          -  known allergy against Midazolam&#xD;
&#xD;
          -  known allergy against Fentanyl&#xD;
&#xD;
          -  pregnancy or breast-feeding&#xD;
&#xD;
          -  unable or unwilling to give informed consent&#xD;
&#xD;
          -  unable or unwilling to follow investigator's instructions&#xD;
&#xD;
          -  unable or unwilling to comply with study protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Burkhard Gustorff, Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wilhelminenspital Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Schmerzdiagnostik / Clinical Research Unit</name>
      <address>
        <city>Vienna</city>
        <zip>1190</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>December 6, 2015</study_first_submitted>
  <study_first_submitted_qc>December 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2015</study_first_posted>
  <last_update_submitted>March 10, 2016</last_update_submitted>
  <last_update_submitted_qc>March 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wilhelminenspital Vienna</investigator_affiliation>
    <investigator_full_name>Burkhard Gustorff</investigator_full_name>
    <investigator_title>Univ.Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>Midazolam</keyword>
  <keyword>Fentanyl</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

